Page 83 - Read Online

Ma et al. J Cancer Metastasis Treat 2022;8:25 Journal of Cancer
DOI: 10.20517/2394-4722.2022.17
Metastasis and Treatment

Review Open Access

The peripheral T-cell lymphoma: can we pivot from
the chemotherapy-predicated paradigm?

Helen Ma 1,2 , Enrica Marchi 3
1
Section of Hematology/Oncology, VA Long Beach Healthcare System, Long Beach, CA 90822, USA.
2
Division of Hematology/Oncology, University of California, Irvine, Orange, CA 92868, USA.
3
Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.
Correspondence to: Dr. Helen Ma, Section of Hematology/Oncology, VA Long Beach Healthcare System, 5901 East 7th St., Long
Beach, CA 90822, USA. E-mail: Helen.Ma@va.gov

How to cite this article: Ma H, Marchi E. The peripheral T-cell lymphoma: can we pivot from the chemotherapy-predicated
paradigm? J Cancer Metastasis Treat 2022;8:25. https://dx.doi.org/10.20517/2394-4722.2022.17

Received: 17 Feb 2022 First Decision: 24 Apr 2022 Revised: 24 Apr 2022 Accepted: 24 May 2022 Published: 29 Jun 2022
Academic Editors: Lucio Miele, Francesca Montanari Copy Editor: Fangling Lan Production Editor: Fangling Lan

Abstract
Peripheral T-cell lymphomas (PTCL) are uncommon and aggressive diseases that are difficult to study.
Combination chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone has been the
mainstay of treatment for almost 30 years, but outcomes remain poor. The development of new targeted therapies
is changing the landscape of how we treat patients with these difficult diseases. For instance, the addition of
brentuximab vedotin to combination chemotherapy enhanced the outcomes in patients with CD30-positive
anaplastic large cell lymphomas, but there is still a need for better therapies in the other numerous subtypes. Here
we discuss the data for the existing treatment paradigm of PTCL as well as the merits of shifting toward a
chemotherapy-free approach.

Keywords: Peripheral T-cell lymphomas, PTCL, chemotherapy-free, epigenetics, targeted therapy

INTRODUCTION
Peripheral T-cell lymphomas (PTCL) are a group of diseases that are both very heterogeneous and rare,
making it a significant challenge to advance care for patients affected by these diseases. The most recent
World Health Organization (WHO) classification recognizes 29 distinct types, with the cell-of-origin of
these non-Hodgkin lymphomas (NHL) arising from post-thymic T- and natural killer (NK) cells . Due to
[1]

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jcmtjournal.com